| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Jul―24 |
LW-AFC Protects Against Neurological and Neuropsychiatric Effects of SARS-CoV-2 Spike Protein in Mice |
Wenyi Xiao, Jiao Wang, Jianhui Wang, Lu Han, Donghui Wei, Wenxia Zhou, Ning Jiang |
| 2 |
[GO] |
2025―Mai―14 |
Correction to ‘Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis’ |
|
| 3 |
[GO] |
2025―Jan―06 |
Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis |
Per-Jostein Samuelsen, Björn Wettermark, Fredrik Nyberg, Mohammadhossein Hajiebrahimi |
| 4 |
[GO] |
2024―Mrz―12 |
Matrix metalloproteinases are associated with severity of disease among COVID-19 patients: A possible pharmacological target |
Gisele Lopes Cavalcante, Lívia Pimenta Bonifacio, Jéssica Maria Sanches-lopes, Fernanda Guioti Puga, Felipe Santos de Carvalho, Fernando Bellissimo-Rodrigues, Jose Eduardo Tanus-Santos |
| 5 |
[GO] |
2023―Okt―31 |
Trends in medication use at the onset of and during the COVID-19 pandemic in the Republic of Ireland: an interrupted time series study |
Molly Mattsson, Jung Ah. Hong, John Scott Frazer, Glenn Ross Frazer, Frank Moriarty |
| 6 |
[GO] |
2023―Apr―11 |
Vitamin D and SARS-CoV-2 |
Sofie-Louise Feentved Ødum, Martin Kongsbak-Wismann |
| 7 |
[GO] |
2022―Sep―27 |
GABA
A
receptors as targets for anaesthetics and analgesics and promising candidates to help treat coronavirus infections: a mini-review |
Yujia Luo, Thomas Balle |
| 8 |
[GO] |
2022―Jun―21 |
Initiation of antihypertensive drugs to patients with confirmed COVID-19 - a population-based cohort study in Sweden |
Salar Issa Mousa, Fredrik Nyberg, Mohammadhossein Hajiebrahimi, Rebecka Bertilsson, Jonatan Nåtman, Ailiana Santosa, Björn Wettermark |
| 9 |
[GO] |
2021―Nov―23 |
Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality. Time for a suitable proposal |
Sergio Pandolfi, Salvatore Chirumbolo, Giovanni Ricevuti, Luigi Valdenassi, Geir Bjørklund, Roman Lysiuk, et al. (+3) Monica Daniela Doşa, Larysa Lenchyk, Serafino Fazio |
| 10 |
[GO] |
2021―Okt―27 |
Transfer of chemicals to a secondary container, from the introduction of new labelling regulation to COVID-19 lockdown: a retrospective analysis of exposure calls to the Poison Control Centre of Rome, Italy, 2017-2020 |
Michele Stanislaw Milella, Maria Caterina Grassi, Alessia Gasbarri, Valeria Mezzanotte, Francesco Pugliese, Gabriella Vivino |
| 11 |
[GO] |
2021―Sep―08 |
Home therapy of COVID-19 at the earliest may greatly prevent hospitalization |
Sergio Pandolfi, Salvatore Chirumbolo |
| 12 |
[GO] |
2021―Mai―12 |
An update on emerging therapeutics to combat COVID-19 |
Naveed Nazir Shah, Showkat Ul Nabi, Showkeen Muzamil Bashir, Muzafar Ahmad Rather, Qudratullah Kalwar, Sofi Imtiyaz Ali, et al. (+2) Wajid Mohammad Sheikh, Alveena Ganai |
| 13 |
[GO] |
2021―Feb―06 |
Choppy Waters: The Importance of Accounting for Shifting Drug Utilization During the COVID-19 Pandemic in Future Observational Drug-related Studies |
Ahmad Shakeri, Tara Gomes, Katie Suda, Mina Tadrous |
| 14 |
[GO] |
2020―Nov―25 |
The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 In Vitro |
Valeria Cagno, Gaelle Magliocco, Caroline Tapparel, Youssef Daali |
| 15 |
[GO] |
2020―Nov―12 |
Camostat Mesylate against SARS-CoV-2 and COVID-19 - Rationale, Dosing and Safety |
Peter Breining, Anne Lier Frølund, Jesper Falkesgaard Højen, Jesper Damsgaard Gunst, Nina B. Staerke, Eva Saedder, et al. (+5) Manuel Cases-Thomas, Paul Little, Lars Peter Nielsen, Ole S. Søgaard, Mads Kjolby |
| 16 |
[GO] |
2020―Okt―25 |
COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin? |
Ali Saeedi-Boroujeni, Mohammad-Reza Mahmoudian-Sani, Mohammad Bahadoram, Arash Alghasi |
| 17 |
[GO] |
2020―Sep―21 |
COVID-19 clinical trials: ethical and scientific consequences of the RECOVERY trial results |
Rafael Dal-Ré, Raphaël Porcher, Christian Gluud |
